DIABRISK-SL trial: Further consideration of age and impact of imputations

Gkioni, E ORCID: 0000-0002-0396-5460, Glonti, K, Dodd, S ORCID: 0000-0003-2851-3337 and Gamble, C ORCID: 0000-0002-3021-1955 (2019) DIABRISK-SL trial: Further consideration of age and impact of imputations BMC Medicine, 17 (1). 121-. ISSN 1741-7015, 1741-7015

Text Letter to the Editor_EG.docx - Author Accepted Manuscript Download (46kB)

Abstract

Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality worldwide. Early interventions may help to delay or prevent onset of cardiometabolic endpoints of clinical importance to T2DM patients. Wijesuriya et al. (BMC Med 15:146, 2017) published results of a randomised controlled trial in Sri Lanka testing the effect of two lifestyle modification programmes of varying intensity in participants aged 5-40 years with risk factors for T2DM. The intervention measured the impact of the two programmes on the primary composite endpoint consisting of various predictors of cardiometabolic disease. The authors concluded that the more intensive programme significantly reduced the incidence of predictors of cardiometabolic disease. Further, they delivered a large-scale intervention with restricted resources with widespread acceptance as demonstrated by the high uptake rate. However, we believe that further analysis is required to fully understand the potential for benefit, particularly in relation to age, retention and missing data.

Item Type:	Article
Uncontrolled Keywords:	Randomised controlled trial, Lifestyle modification programme, Type 2 diabetes mellitus
Depositing User:	Symplectic Admin
Date Deposited:	06 Jun 2019 15:06
Last Modified:	01 Mar 2026 08:49
DOI:	10.1186/s12916-019-1361-2
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3042469
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.